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Abstract
Tissue engineering of the small intestine offers an
alternative to long-term intravenous nutrition and
transplantation in patients with intestinal failure. Initial
work, although encouraging, is limited by the volume of
neonatal tissue required to produce a small neomucosal cyst.
Our novel approach is to implant tubular poly-lactide-co-
glycolide (PGLA) foam scaffolds subcutaneously. The aim
of this study was to investigate whether these scaffolds
would support growth of intestinal neomucosa. PGLA
scaffolds were implanted subcutaneously into 8 Lewis rats;
after 5 weeks, ‘organoid units’ were injected into the
lumens. Tissue was assessed histologically after harvesting
and quantitative immunohistochemistry was performed
using antibodies against vascular endothelial growth factor
(VEGF), vascular endothelial growth factor receptor 2
(VEGF-R2), fibroblast growth factor basic (bFGF) and
fibroblast growth factor receptor 2 (FGF-R2). At 4 weeks
post organoid unit implantation, clearly recognisable
mucosa and submucosa was present on the luminal surface
of the scaffold. Densities of VEGF and VEGF-R2 positive
cells increased with time post organoid unit implantation.
This pilot study demonstrates that it is possible to tissue
engineer small intestinal neomucosa using subcutaneously
implanted PLGA scaffolds. The yield of the process
compares favourably to the published literature. Further
work is required to optimise the technique.
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Introduction
Short bowel syndrome (SBS) is characterised by
gastrointestinal fluid loss, malabsorption and progressive
malnutrition; if fluids, electrolytes and nutrients are not
replaced, patients become dehydrated and malnourished.
This may ultimately be fatal. The commonest cause of
SBS is loss of functional absorptive intestinal surface
usually due to extensive small bowel resection. Patient
survival is dependent on long-term parenteral nutrition,
with its associated morbidity and mortality.  With the
provision of parenteral nutrition in the home setting,
survival is quoted at 75% at 5 years and 60% at 10 years;
patients with very short residual intestine (<50cm) have
the worst prognosis (Messing et al., 1999). Surgical
treatment to lengthen the bowel has been described in
children but is of limited value in adults (Bianchi, 1980).
Small intestinal transplantation can be considered but it
requires aggressive immunosupression (Abu-Elmagd et
al., 2002) and survival rates are not yet as high as other
solid organ grafts. The one year graft survival for intestinal
grafts has recently been quoted at 65% with patient
survival at 77% (Grant et al., 2005). Scarcity of donor
organs is another major limitation to transplantation,
especially in the paediatric population.
A novel approach to the treatment of SBS has been
the development of tissue engineered small bowel
constructs. The technique behind this concept is to employ
an artificial biodegradable scaffold to promote soft tissue
growth and support an epithelium within its lumen (Gabe
et al., 2004; Vacanti, 2003). Polylactic acid (PLA),
polyglycolic acid (PGA) and their copolymers have been
used in small intestinal tissue engineering in rodents as
synthetic structures to support the adherence and growth
of ‘organoid units’ (Choi et al., 1998; Mooney et al.,
1994). These organoid units consist of intestinal epithelial
stem cells, enterocytes and stromal cells. They are derived
from neonatal intestinal tissue by a process of limited
digestion using collagenase and dispase which yields a
mixture of intestinal crypts and villi (Evans et al., 1992).
Vacanti and colleagues have developed a technique in
which organoid units are placed onto a tubular copolymer
scaffold which is then implanted into the peritoneum of
rodent models (Choi et al., 1998). They have demonstrated
the development of a “cyst like” structure consisting of a
neomucosal surface with the histological characteristics
of small intestine; physiological studies reveal an electric
potential across the neomucosa suggesting active transport
(Choi et al., 1998). These cystic structures have been
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successfully incorporated into healthy rat small intestine
(Kaihara et al., 1999a; Kaihara et al., 1999b; Kaihara et
al., 2000; Kim et al., 1999) and indirect studies suggest
that they may have absorptive potential (Grikscheit et al.,
2004). Unfortunately, the yield of the published
methodology remains low and a large quantity of donor
tissue is required to produce each tissue engineered cyst
(Choi et al., 1998; Grikscheit et al., 2004).
Our group has developed a poly-lactide-co-glycolide
(PLGA) foam into a tubular structure with transverse and
longitudinal porosity of controlled size. The scaffold
produced has a wall thickness of 1mm and luminal
diameter of 2mm. The pores within the scaffold are
approximately 100µm in size and form transverse and
longitudinal channels that allow cell migration throughout
the scaffold (Day et al., 2004a). When implanted
subcutaneously into a rat model there is progressive
infiltration of cellular material into the scaffold with blood
vessels present within this structure (Day et al., 2004a).
Angiogenesis is vital to the survival and development of
mucosal tissue within an artificial scaffold since, without
vascularisation, gas and nutrient exchange relies almost
entirely on passive diffusion. It is likely that angiogenesis
is stimulated by growth factors such as vascular endothelial
growth factor (VEGF) and fibroblast growth factor basic
(bFGF) which are secreted by fibroblasts infiltrating the
scaffold. VEGF is believed to be one of the major regulators
of blood vessel formation (Ferrara, 2000) and bFGF is
also highly angiogenic. Both VEGF and bFGF are thought
to play an integral role in the neo-vascularisation of
bioengineered tissues (Soker et al., 2000).
Our group has demonstrated that pre-implantation of
scaffolds allows population by fibroblasts and initial
angiogenesis, and have described the time course of
cellular infiltration of tubular scaffolds and concomitant
angiogenesis (Day et al., 2004b; Day et al., 2004a). It is
our belief that a cellularised scaffold will facilitate the
growth and development of implanted organoid tissue thus
decreasing the number of organoid units required to
develop a viable neomucosa. The purpose of this study
was to evaluate a novel model of intestinal tissue
engineering using pre-implanted subcutaneous scaffolds
and to, using stereological methods, quantify those cells




Experiments were performed using inbred male Lewis rats
(Harlan UK Ltd). All animals were maintained and handled
in accordance with the Animals (Scientific Procedures)
Act 1986 and the study performed following guidelines
stipulated by the UK Home Office. All animals were kept
under standard laboratory conditions and fed a commercial
pelleted diet.
Scaffold implantation
A tubular PLGA foam construct with a 2mm internal
diameter and 1mm wall thickness was created using the
thermally induced phase separation (TIPS) technique
described in our previous study (Day et al., 2004a). This
construct was divided into 12 scaffolds each measuring
10mm in length. The scaffolds were sterilized by exposure
to ultraviolet light. 2.2mm external diameter silicone tubing
(Vygon UK Ltd) was placed inside each scaffold to
maintain luminal patency. 8 adult male rats weighing 235-
280g were anaesthetised using 0.25ml IM Hypnorm
(0.315mg/ml fentanyl citrate and 10mg/ml fluanisone) and
1mg IP diazepam. 12 scaffolds (1-2 per animal) were
implanted into subcutaneous pockets formed in the inguinal
folds of the 8 rats. Skin was closed with 3/0 Mersilk®
sutures (Ethicon, Johnson & Johnson Medical Ltd, UK)
and the scaffold was left in situ for 5 weeks. 8mg/kg IM
gentamicin was administered post-operatively.
Organoid unit manufacture
Organoid units were prepared using a modification of the
method described by Evans et al. (Evans et al., 1992). A
single 7 day old male Lewis rat was sacrificed by cervical
dislocation. The complete length of small bowel was
removed and cleaned free of mesentery. The intestine was
opened along its length and divided into approximately
2mm lengths and washed 6 times in a solution of 2%
glucose in Hanks’ balanced salt solution (HBSS). The
tissue was then manually chopped into approximately
1mm3 pieces and digested for 25 minutes using a solution
of 300U/ml collagenase, Clostridium histiolyticum, type
XI-S, (Sigma-Aldrich, Dorset, UK) and 0.1mg/ml dispase,
Bacillus polymyxa (Gibco BRL, Life Technologies, UK)
in HBSS at room temperature on an orbital shaker. The
supernatant was discarded and the digestion was repeated
twice. After the third digestion the supernatant was
preserved and the reaction terminated by addition of
Dulbecco’s modified Eagle’s medium (DMEM)
supplemented with 2.5% foetal calf serum, 2% sorbitol
and 60µg/ml penicillin and streptomycin solution (Gibco
BRL, Life Technologies, UK). Organoid units were
purified by three rounds of centrifugation at 250xg for 3
minutes followed by removal of supernatant and
resuspension in supplemented DMEM. After the final
centrifugation, the organoid units were resuspended in
extracellular matrix (ECM) gel (Sigma-Aldrich, Dorset,
UK) supplemented with 50ng/ml hepatocyte growth factor
(HGF) (PeproTech EC Ltd, UK).
Organoid implantation and harvest
Five weeks after initial scaffold implantation, 6 of the
scaffold implanted rats were anaesthetised using the
protocol above. Incisions were made over the subcutaneous
scaffolds and the inner silicone tubing was removed. 20µL
of organoid unit suspension was micropipetted into the
lumen of each scaffold. The skin was closed with 3/0
Mersilk® sutures (Ethicon, Johnson & Johnson Medical
Ltd, UK). Rats were sacrificed by lethal injection of sodium
pentobarbitone at 0 (this equates to 5 weeks scaffold
implantation with no organoid units injected), 1, 2 and 4
weeks after organoid unit implantation and the explanted
tissue removed. 3 scaffolds were obtained for each time
point. The scaffolds were fixed in 10% neutral buffered
formal saline for a minimum of one week.
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Tissue preparation
Following fixation, the length of each explanted tissue was
measured. The scaffold was then divided transversely into
equal quarters. Each quarter was placed cut face down
into a cassette and processed to paraffin using routine
laboratory techniques. One full face 5µm section was cut
and stained with haematoxylin and eosin (H&E) for routine
examination. Additional sections were cut at 3µm for
immunohistochemsitry and mounted onto ATPS coated
slides.
Immunohistochemistry
Sections were de-paraffinised in xylene, re-hydrated by
passing through decreasing concentrations of industrial
methylated spirit (IMS) (100%-70%) and rinsed in distilled
water. For VEGF receptor-2 (VEGF-R2) staining, sections
underwent antigen retrieval using trypsin digestion for 30
minutes at 37oC (Sigma-Aldrich, Dorset, UK). All sections
were rinsed in distilled water and treated with 0.3%
hydrogen peroxide in methanol for 30 minutes to block
endogenous peroxidase activity before being washed in
distilled water for 3x 3 minute cycles; the wash was then
repeated with phosphate buffered saline (PBS). Sections
were treated with normal goat serum 1:200 (Vector
Laboratories, Peterborough, UK) for 20 minutes to prevent
non-specific staining before being incubated with the
primary antibody. Primary antibodies used were as follows:
rabbit polyclonal VEGF (Santa Cruz Biotechnology Inc
through Autogen Bioclear UK Ltd) 1:100 dilation in bovine
serum albumin (BSA) incubated at 4oC for 48hours, rabbit
polyclonal VEGF-R2 (Abcam, Cambridge, UK) 1:50
dilution in BSA incubated at 4oC for 24 hours, rabbit
polyclonal FGF basic (bFGF) (Abcam, Cambridge, UK)
1:100 dilution in BSA incubated at 4oC for 24 hours, rabbit
polyclonal FGF receptor 2 (FGF-R2) (Abcam, Cambridge,
UK) 1:100 dilution in BSA incubated at 4oC for 24 hours.
Sections were subsequently washed in PBS 3x 3 minute
cycles and then incubated further with normal goat serum
and anti rabbit secondary antibody (Vector Laboratories,
Peterborough, UK) 1:200 dilution in PBS at room
temperature for 2 hours for VEGF and VEGF-R2 and 30
minutes for bFGF and FGF-R2. Following another 3x 3
minute wash in PBS, sections were incubated with an
Avidin Biotin-peroxidase Complex using the Vectostain
Elite ABC kit (Vector Laboratories, Peterborough, UK).
Immunoreactivity was visualized with a diaminobenzidine
(DAB) substrate (Vector Laboratories, Peterborough, UK).
Finally sections were counterstained with Gill’s
haematoxylin for 1½ minutes.
Stereological analysis
The numerical density of positive staining cells was
estimated using 2D stereological techniques for each
growth factor and receptor. An unbiased counting frame
generated by a digital software package (Kinetic Imaging
Stereology 5.0) was projected onto the histological image.
Starting at a random position at the top left corner and
following a tessellating pattern, positive cells within the
unbiased counting frame and obeying the rules of the frame
were included in the final estimate. Each section was
viewed at final magnification of x630 and an average of
40 fields of view were analysed for each growth factor or
receptor. Data for each field was used to obtain the total
number of cells per unit area (NA) using the following
equation:
Where NA = number per unit area, ∑Q = sum of positive
cells counted, ∑P = sum of unbiased counting frames and
fA  = area of the frame.
Statistical analysis
The mean and standard error of the mean (SEM) of the
numerical density of positively stained cells were
calculated for each growth factor and receptor. The results
were analysed using linear regression analysis (Sigma Stats
version 2). Calculated p values are reported and were
considered statistically significant if p<0.05.
Results
Macroscopic appearance
All animals survived the duration of the study with no
adverse effects. At weeks 0, 1, 2 and 4 after organoid unit
implantation firm spheroid cyst like structures measuring
approximately 10mm in length and 5mm in diameter were
identified at the site of implantation.
Histological appearance
Low magnification histological examination of H&E
stained sections harvested at 5 weeks after scaffold
implantation but with no organoid implantation revealed
no identifiable mucosa or submucosa. However, there were
numerous inflammatory cells and fibrosis on the internal
aspect of the scaffold. At higher magnification fibroblasts,
macrophages, monocytes and scattered polymorphs were
identified within the scaffold. Groupings of these cells
within the scaffold were seen in longitudinal lacunae from
the internal to external surface of the scaffold. The scaffold
was well vascularised and completely encapsulated by a
fibrous band of tissue.  At one position, corresponding to
the join in the scaffold, a cellular fibrin lattice connected
the internal and external surfaces of the scaffold.
At week 1 after organoid unit implantation the main
structure of the scaffold was similar to that seen at week 5
weeks scaffold implantation but with no organoid
implantation. The lumen was entirely filled with an
undifferentiated tissue mass which was transversely
bisected by a fibrous tissue (see Figure 1). At week 2 the
histological appearances were essentially unchanged. No
mucosal tissue was present at either week 1 or week 2.
At week 4 after organoid unit implantation, low
magnification appearance of the scaffold was similar to
previous weeks (see Figure 2(a)). However, at high
magnification there was evidence of capillary formation
with the presence of endothelial cells (see Figure 2(b)).
On the inner surface of the scaffold there was a layer
consisting of recognisable mucosa and submucosa; the
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Figure 1: H&E staining of scaffold at 1 week after
organoid implantation. 1 week after implantation of
the organoid units there is no evidence of a luminal
neomucosa. At this time point, 6 weeks after scaffold
implantation, there is extensive infiltration of the PLGA
scaffold with evidence of vascularisation. At higher
magnification, fibroblasts, macrophages and
monocytes are identifiable.
Figure 2: (a) H&E staining of scaffold at 4 weeks
after organoid implantation. 4 weeks after organoid
unit implantation there is evidence of mucosa and
submucosa lining the entire circumference of the
luminal surface of the scaffold. The appearance of the
scaffold is similar to at 1 week after organoid
implantation. (b) H&E staining of scaffold at 4 weeks
after organoid implantation. At high magnification,
the appearance of the mucosa and submucosa lining
the luminal surface of the PLGA scaffold is similar to
that of normal small intestinal tissue. There is columnar
epithelium containing mucin producing goblet cells
which has developed into crypts and villi in some
areas. The submucosa contains macrophages,
fibroblasts and other inflammatory cells.
Figure 3: Immunohistochemical staining with primary
antibody against VEGF at 4 weeks after organoid
implantation. Cells staining positively for VEGF are
present at all time points although the density of
positively staining cells increases with time. VEGF is
present in vascular endothelial cells and is also secreted
by fibroblasts. At 4 weeks after organoid unit
implantation there is evidence of capillary formation
with VEGF positive cells arranged in cylindrical
structures.
lumen of the scaffold contained what appeared to be
cellularised inorganic material, cellular debris and
apoptotic cells together with necrotic debris and
macrophages.
Growth factors and receptor quantification
Cells expressing VEGF, VEGF-R2, bFGF and FGF-R2
were present at all time points i.e. from pre-organoid unit
implantation to 4 weeks post implantation. Stereological
quantification was performed in two different regions, the
morphological architecture was similar to that seen in well
developed small intestinal tissue. The mucosa consisted
of columnar epithelial cells together with goblet cells
containing what appeared to be mucin additionally there
were well defined crypts showing columnar and goblet
cells arranged in a rosette formation. The lumen of a small
number of the crypts contained cellular debris and
apoptotic bodies. The submucosa contained macrophages,
fibroblast and other inflammatory cells. At the base of the
submucosal layer there was a densely fibrous layer. The
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scaffold, and the luminal region consisting of the mucosa
and submucosa. There was a significant increase in the
density of cells expressing VEGF and VEGF-R2 from
week 0 (i.e. pre-organoid implantation) to week 4 within
the scaffold (p<0.001 for both - see Figures 3 and 4(a)).
The numerical density of cells expressing VEGF-R2 was
consistently higher than the numerical density of cells
expressing the accompanying growth factor in both the
scaffold and the neo-mucosal region. Within the
submucosal and mucosal region the density of cells
expressing VEGF-R2 was considerably higher than those
expressing VEGF. Neither bFGF nor FGF-R2 showed any
statistically significant increase in the numerical density
within the scaffold over the 4 weeks post implantation
period. The numerical density of cells expressing FGF-
R2 was higher than those expressing bFGF in the scaffold
only. Within the submucosal and mucosal region, bFGF
and FGF-R2 numerical densities were identical; however,
it was higher than that observed within the scaffold (see
Figure 4(b)).
Discussion
In this study we have successfully employed a PLGA
scaffold, similar to that developed in our preliminary
investigation (Day et al., 2004a), as a framework on which
to grow tissue engineered neomucosa by implantation of
organoid units derived from neonatal intestinal tissue. 5
weeks after implantation, the scaffold appearance was
similar to that previously described (Day et al., 2004a).
By week 4 after implantation of the organoid units, clearly
recognisable mucosa and submucosa showing histological
features similar to small intestine were present. The
neomucosa consisted of a columnar epithelium containing
goblet cells and there was organisation into crypts and villi.
In conjunction with quantitative techniques,
immunohistochemistry was used to evaluate a number of
growth factors and their associated receptors. The presence
of VEGF, VEGF-R2, bFGF and FGF-R2 clearly
demonstrates that both the scaffold and the neomucosa
are being vascularised, a precursor to neomucosal
functionality.
2D stereological techniques were used for the first time
to investigate cellularisation of the scaffold and tissue
Figure 4: (a) Density of cells (NA) positively staining for VEGF and VEGF-R2. The numerical density of positively
staining cells in the scaffold at weeks 0, 1, 2 and 4 and in the neomucosa at week 4 (indicated by *) is shown.
Density of cells in the scaffold staining positively for VEGF and for VEGF-R2 increased with time. Error bars
represent standard error of the mean. (b) Density of cells (NA) positively staining for bFGF and FGF-R2. The
numerical density of positively staining cells in the scaffold at weeks 0, 1, 2 and 4 and in the neomucosa at week 4
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engineered neomucosa. Stereological techniques are
unbiased  and design based (Gundersen et al., 1987;
Gundersen et al., 1988). Estimates derived from single
planar counts (i.e. a single histological section) may have
inherent bias associated with them unless stereological
techniques are used. Depending upon where within the
tissue the section is obtained and which field of view is
examined results can be influenced or biased unless a
systematic sampling regime is employed (Gundersen et
al., 1987). Such inaccuracies are avoided by using
stereological techniques and therefore comparisons
between samples are more meaningful.
In addition to the use of a novel scaffold material and
a more quantitative histological analysis, the methodology
used in this study differs from that in the published
literature (Choi et al., 1998; Grikscheit et al., 2004; Kaihara
et al., 1999b; Kim et al., 1999) in two important aspects:
the site of implantation and the timing of implantation
relative to seeding with donor tissue. In this study the
PLGA scaffolds were implanted subcutaneously rather than
into the peritoneum. There are advantages and
disadvantages to this approach. A peritoneal implantation
site arguably provides a more anatomically and
physiologically optimal environment for bowel growth and
development than a subcutaneous implantation site.
However the advantage of a subcutaneous scaffold is that
it is more easily accessible allowing removal of the silicone
inner tube and implantation of organoid units onto the
cellularised scaffold. In addition, this technique also allows
transcutaneous injection or infusion of modulatory peptides
and growth factors directly into the construct. This may
allow the yield of the process to be amplified and may
also allow the construct to be used as an experimental
model of bowel growth and regeneration. Furthermore, if
these techniques were extrapolated to a clinical scenario,
subcutaneous scaffold implantation would be significantly
less hazardous than peritoneal implantation in patients who
are likely to have undergone a number of abdominal
operations with resultant scarring and formation of dense
intraperitoneal adhesions.
The other major difference between the methodology
described in this study and that of the Vacanti group is that
in this study the scaffolds were implanted five weeks prior
to seeding with organoid units rather than immediately after
seeding. Previous work has demonstrated that within 4
weeks of subcutaneous implantation PLGA scaffolds
become infiltrated with pro-angiogenic cellular material
and there is evidence of early blood vessel formation (Day
et al., 2004a). The initial concentrations of VEGF and
VEGF-R2 positive cells in the non-mucosal tissue at week
0 (5 weeks after scaffold implantation but prior to organoid
unit implantation) suggest that the onset of angiogenesis
had begun prior to organoid unit implantation. VEGF-R2
is expressed almost exclusively by endothelial cells and it
is therefore probable that endothelial cells had infiltrated
the scaffold during the five weeks between scaffold
implantation and seeding of organoid units. The increase
in VEGF and VEGF-R2 seen in the outer non-mucosal
region of the test tissue over the time course of the
experiments strongly suggests progression of angiogenesis
after organoid unit seeding. It is difficult to compare
absolute expression of either growth factors or their
receptors in the highly organised neomucosa with that in
the non-mucosal scaffold due to differences in tissue
morphology and cell type.
The aim of scaffold pre-implantation was to improve
the environment into which the organoid units were
introduced with the aim of increasing the overall yield of
the process. Although the work produced by Vacanti and
colleagues is impressive, especially in respect to the range
of intestinal mucosa that they have successfully engineered
(Grikscheit et al., 2003a; Grikscheit et al., 2003b;
Grikscheit et al., 2004; Kim et al., 1999), the methodology
used remains inefficient. Approximately one entire
neonatal rat intestine is required to produce the organoid
units to populate successfully a single scaffold and produce
a 1.5cm2 area of neomucosa (Choi et al., 1998). In this
study we were able to populate 9 scaffolds, each with an
internal surface area of 0.6cm2, with organoid units
extracted from a single neonatal rat intestine. This
represents an almost 4-fold improvement in yield compared
with the published literature (Grikscheit et al., 2004).
This study is a pilot for further research using a
subcutaneous model for intestinal tissue engineering. It is
clearly important to extend the time course of this study in
order to observe the development of the neomucosa. Future
experiments will also investigate other methods to improve
the yield of the tissue engineering process. One possible
avenue is the use of exogenous growth factors to stimulate
development of the neomucosa. These might be attached
to the scaffold, injected transcutaneously into the scaffold,
or might be administered systemically. A single published
study has demonstrated increased neomucosal growth
following administration of glucagon-like peptide 2 (GLP-
2) (Ramsanahie et al., 2003). The further and optimal use
of exogenous growth factors will depend on an increased
knowledge of the spatial and temporal expression of the
different growths factors and their receptors in order to
allow more targeted use. Finally, it may be possible to use
stem cell populations, rather than, or in combination with
neonatal tissue to populate the scaffolds and thus reduce
the requirement for neonatal tissue. Bone marrow cells
have been used successfully in the tissue engineering of
vascular structures (Hibino et al., 2005).
Conclusions
The technology exists to create small intestinal neomucosa
using tissue engineering techniques. This holds the promise
of creating replacement intestinal surface for patients with
short bowel syndrome. The use of autologous cells to create
biocompatible tissue engineered intestinal constructs has
many benefits including the avoidance of problems
associated with transplantation, stimulation of natural
biological mechanisms for repair and remodelling,
complete biocompatibility and the potential for further
growth. In addition, tissue engineered neomucosa could
be used as a model in developing an understanding of
intestinal development and repair as well as to test drug
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development and administration. However, at present the
process of intestinal tissue engineering is inefficient with
a large volume of neonatal tissue being required to produce
a small volume of neomucosa. This study suggests that
the yield of the process can be improved by pre-
implantation of the bioresorbable PLGA scaffold prior to
application of donor tissue. Our findings suggest that
angiogenesis occurs during this pre-implantation period
and continues after seeding of the scaffold with organoid
units. Further work is needed to elucidate the optimal pre-
implantation period, to investigate other ways to improve
the yield of the tissue engineering process and to identify
other potential sources of donor tissue.
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Discussion with Reviewers
A Curtis: Do you have evidence that proliferation and
cell movement on these scaffolds match the normal in vivo
situation in organogenesis?
Authors: Since we did not harvest tissues at hours and
early days post application of the organoid units to the
scaffolds, it is not possible to be certain that the
organogenesis of the tissue grown in this study exactly
follows the routes of proliferation and cell movement that
occur in the normal in vivo situation. However, it is likely
that to achieve the morphological status of these samples,
the organogenic routes must be similar. It would be
expected that cell signalling and feedback mechanisms
associated with growth factors and specific sub-
components of bowel organogenesis would have to be
represented in a similar time and activity progression to
induce the structural integrity seen in these samples. New
studies will address this issue specifically.
DO Meredith: This is a very exciting method, however, a
criticism that could be levelled is the use of neonatal tissue
to produce the necessary mucosal tissue. If, ultimately, the
goal is to move into human regeneration of the small
intestine, how would this problem be overcome if there
would be no source of neonatal tissue?
Authors: It may be possible to use bone marrow derived
cells and/or stem cell populations, rather than, or in
combination with neonatal tissue to populate the scaffolds
and thus reduce the requirement for neonatal tissue. Studies
have shown that bone marrow derived mesenchymal cells
can differentiate into pericryptal myofibroblasts in both
mice and humans (Brittan et al., 2002). A recent study has
shown that in IL-10 knockout mice undergoing bone
marrow transplantation, 30% of colonic subepithelial
myofibroblasts are of bone marrow origin in normal
mucosa, increasing to 45% in inflamed mucosa 3 months
after transplantation (Bamba et al., 2005). It is unknown
whether a similar process occurs in the neomucosa of
intestinal constructs although there is a suggestion that a
developing construct is of exclusive donor origin using
Green Fluorescent Protein labelling (Grikscheit et al.,
2003). However, more sensitive techniques may be
required to investigate whether mesenchymal cells can
become incorporated into a developing intestinal construct.
DO Meredith: Further down the line, do you think that
the system could also be kept entirely in vitro until the
time of final implantation?
Authors: It is possible that artificial scaffolds could be
used to support the growth of intestinal neomucosa in vitro
although this would necessitate a considerably better
understanding of the various growth factors required for
mucosal differentiation and development than is presently
available. An in vitro model could be a useful tool for
assessing the response of intestinal neomucosa to a range
of pharmacological and other stimuli. However, the
advantage of the in vivo model is that it allows
vascularisation of the scaffold which would be difficult to
achieve in vitro and maintain at final implantation.
Vascularisation is essential to the support of the luminal
neomucosa and it is unlikely that the neomucosa would
survive if it were interrupted.
DO Meredith: The developed tissue seems functionally
quite advanced. How would the proposed addition of
growth factors enhance this already developed tissue?
Authors: Targeted administration of exogenous growth
factors has the potential to enhance proliferation of
implanted tissue as well as encourage angiogenesis and
neurogenesis. The aim of this would be to improve the
yield of the tissue engineering process and thereby reduce
the quantity of implanted tissue required to produce the
neomucosa. In addition, exogenous growth factors can be
used to augment mucosal absorptive properties. A single
published study has investigated the effect of glucagon-
like peptide 2 (GLP-2) on small intestinal constructs;
exogenous GLP-2 administration resulted in increased
villous height and increased expression of the Na+/glucose
co-transported (SGLT1) which was most marked when the
intestinal construct was in continuity with native small
intestine (Ramsanahie et al., 2003). The further and optimal
use of exogenous growth factors will depend on an
increased knowledge of the spatial and temporal expression
of the different growths factors and their receptors in order
to allow more targeted use.
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